Information Provided By: 
Fly News Breaks for January 5, 2017
SGEN
Jan 5, 2017 | 13:21 EDT
Leerink analyst Michael Schmidt says Seattle Genetics management told him that today's status update on clinicaltrials.gov is "purely procedural" and that the study has completed enrolling all intended patients. The analyst views the intraday selloff in shares as unwarranted and keeps an Outperform rating on Seattle Genetics.
News For SGEN From the Last 2 Days
There are no results for your query SGEN
